Point72 Asset Management
EWTX icon

Point72 Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Point72 Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$460K Buy
+14,600
New +$421K ﹤0.01% 3153
2025
Q2 		– Sell
-50,000
Closed -$1.1M – 2321
2025
Q1 		$1.1M Buy
+50,000
New +$1.31M ﹤0.01% 1413

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management's EWTX Position: Q1 2025 in Review

Point72 Asset Management sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 106,562 shares — an estimated $2.8M sold.

Point72 Asset Management first reported a position in EWTX in Q2 2023 and held it in 3 quarters. The position peaked at $5.48M in Q4 2023. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Point72 Asset Management reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 Asset Management sold 106,562 Edgewise Therapeutics shares in Q1 2025, an estimated $2.8M.
  • Point72 Asset Management first reported a position in Edgewise Therapeutics in Q2 2023 and held it in 3 quarters.
  • Point72 Asset Management's Edgewise Therapeutics position peaked at $5.48M in Q4 2023.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Point72 Asset Management's 13F filing for Q1 2025, filed 15 May 2025.